including five of AstraZeneca’s patents on its blockbuster inhaler Symbicort. The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing ...

Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...